Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma

Gastroenterology

Volumn 148, Issue 7, 2015, Pages 1383-1391.e6

  Lee, Joon Hyeok ^a   Lee, Jeong Hoon ^b   Lim, Young Suk ^c   Yeon, Jong Eun ^d   Song, Tae Jin ^e   Yu, Su Jong ^b   Gwak, Geum Youn ^a   Kim, Kang Mo ^c   Kim, Yoon Jun ^b   Lee, Jae Won ^e   Yoon, Jung Hwan ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Korea University   (South Korea)

Author keywords

Clinical Trial; IL2; Liver Cancer; NK Cell

Indexed keywords

ALCOHOL; CD3 ANTIBODY; CD56 ANTIGEN; INTERLEUKIN 2;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CD3+ T LYMPHOCYTE; CHILL; CONTROLLED STUDY; COUGHING; CYTOKINE INDUCED KILLER CELL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; KOREA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NATURAL KILLER CELL; OPEN STUDY; OVERALL SURVIVAL; PATIENT SAFETY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; STOMACH CANCER; T LYMPHOCYTE; UNIVERSITY HOSPITAL; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LIVER RESECTION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECONDARY; SOUTH KOREA; TIME; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CYTOKINE-INDUCED KILLER CELLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ETHANOL; FEMALE; HEPATECTOMY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RISK FACTORS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84930018607     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.02.055     Document Type: Article

References (49)

1. M.F. Yuen, C.C. Cheng, and I.J. Lauder Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience Hepatology 31 2000 330 335
2. L. Bolondi, S. Sofia, and S. Siringo Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis Gut 48 2001 251 259
3. E.C. Lai, S.T. Fan, and C.M. Lo Hepatic resection for hepatocellular carcinoma. An audit of 343 patients Ann Surg 221 1995 291 298
4. M. Samuel, P.K. Chow, and E. Chan Shih-Yen Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma Cochrane Database Syst Rev 1 2009 CD001199
5. J.D. Schwartz, M. Schwartz, and J. Mandeli Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials Lancet Oncol 3 2002 593 603
6. J. Bruix, and M. Sherman American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
7. C. Verslype, O. Rosmorduc, and P. Rougier Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl 7 2012 vii41 vii48
8. European Association for the Study of the Liver European Organisation for Research Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
9. I.G. Schmidt-Wolf, P. Lefterova, and B.A. Mehta Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells Exp Hematol 21 1993 1673 1679
10. A.C. Ochoa, G. Gromo, and B.J. Alter Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta J Immunol 138 1987 2728 2733
11. M.R. Verneris, M. Ito, and J. Baker Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma Biol Blood Marrow Transplant 7 2001 532 542
12. P.M. Anderson, B.R. Blazar, and F.H. Bach Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity J Immunol 142 1989 1383 1394
13. B.D. Curti, A.C. Ochoa, and G.C. Powers Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer J Clin Oncol 16 1998 2752 2760
14. I.G. Schmidt-Wolf, S. Finke, and B. Trojaneck Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma Br J Cancer 81 1999 1009 1016
15. T. Takayama, T. Sekine, and M. Makuuchi Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial Lancet 356 2000 802 807
16. D.S. Weng, J. Zhou, and Q.M. Zhou Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas J Immunother 31 2008 63 71
17. D. Hui, L. Qiang, and W. Jian A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma Dig Liver Dis 41 2009 36 41
18. Y. Konomi, T. Sekine, and T. Takayama Cytotoxic activity of CD4+ T cells against autologous tumor cells Jpn J Cancer Res 86 1995 854 860
19. T. Takayama, M. Makuuchi, and T. Sekine Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report Cancer 68 1991 2391 2396
20. T. Takayama, T. Sekine, and Y. Kondo Adjuvant adoptive immunotherapy against hepatocellular carcinoma Hepatology 28 1998 1436 1437
21. F.L. Greene American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual 2002 Springer-Verlag New York
22. J. Bruix, and M. Sherman Practice Guidelines Committee. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
23. P.M. Anderson, F.H. Bach, and A.C. Ochoa Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma Cancer Immunol Immunother 27 1988 82 88
24. M. Beyer, and J.L. Schultze Regulatory T cells in cancer Blood 108 2006 804 811
25. C.M. Diaz-Montero, M.L. Salem, and M.I. Nishimura Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy Cancer Immunol Immunother 58 2009 49 59
26. S.I. Grivennikov, F.R. Greten, and M. Karin Immunity, inflammation, and cancer Cell 140 2010 883 899
27. H. Ungefroren, S. Sebens, and D. Seidl Interaction of tumor cells with the microenvironment Cell Commun Signal 9 2011 18
28. B.F. Zamarron, and W. Chen Dual roles of immune cells and their factors in cancer development and progression Int J Biol Sci 7 2011 651 658
29. F. Korangy, B. Hochst, and M.P. Manns Immune responses in hepatocellular carcinoma Dig Dis 28 2010 150 154
30. G.P. Dunn, L.J. Old, and R.D. Schreiber The immunobiology of cancer immunosurveillance and immunoediting Immunity 21 2004 137 148
31. T. Flecken, N. Schmidt, and H.C. Spangenberg [Hepatocellular carcinoma-from immunobiology to immunotherapy] Z Gastroenterol 50 2012 47 56
32. P.H. Lu, and R.S. Negrin A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency J Immunol 153 1994 1687 1696
33. D. Sangiolo, E. Martinuzzi, and M. Todorovic Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers Int Immunol 20 2008 841 848
34. A. Pievani, G. Borleri, and D. Pende Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity Blood 118 2011 3301 3310
35. Y.C. Linn, S.K. Lau, and B.H. Liu Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell Immunology 126 2009 423 435
36. M.J. Pittet, D.E. Speiser, and D. Valmori Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression J Immunol 164 2000 1148 1152
37. A. Diefenbach, A.M. Jamieson, and S.D. Liu Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages Nat Immunol 1 2000 119 126
38. A.M. Jamieson, A. Diefenbach, and C.W. McMahon The role of the NKG2D immunoreceptor in immune cell activation and natural killing Immunity 17 2002 19 29
39. D. Cosman, J. Mullberg, and C.L. Sutherland ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor Immunity 14 2001 123 133
40. Y.J. Chen, S.H. Yeh, and J.T. Chen Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma Gastroenterology 119 2000 431 440
41. M. Shi, J. Fu, and F. Shi Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection Clin Immunol 132 2009 43 54
42. J. Yin, N. Li, and Y. Han Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study J Clin Oncol 31 2013 3647 3655
43. C.Y. Wu, Y.J. Chen, and H.J. Ho Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection JAMA 308 2012 1906 1914
44. J. Jiang, N. Xu, and C. Wu Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells Anticancer Res 26 2006 2237 2242
45. L. Shi, Q. Zhou, and J. Wu Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer Cancer Immunol Immunother 61 2012 2251 2259
46. F. Hirano, K. Kaneko, and H. Tamura Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res 65 2005 1089 1096
47. H. Amano, H. Tashiro, and A. Oshita Significance of platelet count in the outcomes of hepatectomized patients with hepatocellular carcinoma exceeding the Milan criteria J Gastrointest Surg 15 2011 1173 1181
48. S. Weis, A. Franke, and J. Mossner Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma Cochrane Database Syst Rev 12 2013 CD003046
49. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711